Correlated diffusion imaging

BMC Medical Imaging

Volumn 13, Issue 1, 2013, Pages

  Wong, Alexander ^a   Glaister, Jeffrey ^a   Cameron, Andrew ^a   Haider, Masoom ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ENHANCEMENT; MALE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ARTICLE; METHODOLOGY;

ALGORITHMS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84881149506     PISSN: None     EISSN: 14712342     Source Type: Journal    
DOI: 10.1186/1471-2342-13-26     Document Type: Article

References (31)

1. American Cancer Society Cancer Facts & Figures 2012 2012, Atlanta: American Cancer Society, American Cancer Society.
2. Ren J, et al. MRI of prostate cancer antigen expression for diagnosis and lmmunotherapy. PLoS ONE 2012, 7(60):e38350. 3384648, 22761679.
3. Jemal A, et al. Cancer statistics. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
4. Damber J-E, et al. Prostate cancer. Lancet 2008, 371:1710-1721. 10.1016/S0140-6736(08)60729-1, 18486743.
5. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003, 361:1045-1053. 10.1016/S0140-6736(03)12833-4, 12660074.
6. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-864. 10.1016/S0140-6736(03)12713-4, 12642065.
7. Stenman J, et al. Prostate-specific antigen. Semin Cancer Biol 1999, 9:83-93. 10.1006/scbi.1998.0086, 10202130.
8. Chou R, et al. Screening for prostate cancer - a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011, 155(11):762-771. 10.7326/0003-4819-155-11-201112060-00375, 21984740.
9. Norberg M, et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997, 50:562-566. 10.1016/S0090-4295(97)00306-3, 9338732.
10. Beerlage HP, et al. Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology of radical prostatectomy specimen. Prostate Cancer Prostatic Dis 2001, 4:56-62. 10.1038/sj.pcan.4500495, 12497063.
11. Olafsen T, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007, 30:396-405. 10.1097/CJI.0b013e318031b53b, 17457214.
12. Lapi SE, et al. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Nucl Med 2009, 50:2042-2048.
13. Lepin EJ, et al. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 2010, 37:1529-1538. 10.1007/s00259-010-1433-1, 2903645,2903645, 20354850.
14. Giovacchini G, et al. PSA doubling time for prediction of 11C choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:1106-1116. 10.1007/s00259-010-1403-7, 20306038.
15. Turkbey B, et al. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 2009, 6:191-203. 10.1038/nrurol.2009.27, 3520096, 19352394.
16. Khoo VS, et al. Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol 1999, 72:590-597.
17. Debois DF, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys 1999, 45:857-865. 10.1016/S0360-3016(99)00288-6, 10571190.
18. Jackson AS, et al. Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning. Br J Radiol 2007, 80:926-933. 10.1259/bjr/51363812, 17908816.
19. Choi YJ, et al. Functional MR imaging of prostate cancer. RadioGraphics 2007, 27:63-75. 10.1148/rg.271065078, 17234999.
20. Koh DM, Padhani AR. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006, 79:633-635. 10.1259/bjr/29739265, 16793851.
21. Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magnetic Reson Imaging 2004, 20:654-661.
22. Woodfield CA, et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol 2010, 194:316-322.
23. Turkbey B, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?. Radiology 2011, 258:488-495. 10.1148/radiol.10100667, 3029887, 21177390.
24. Haider MA, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007, 189:323-328.
25. Barentsz JO, et al. ESUR prostate MR guidelines. Eur Radiol 2012, 22(4):746-757. 10.1007/s00330-011-2377-y, 3297750, 22322308.
26. Algaba F, Montironi R. Impact of prostate cancer multifocality on its biology and treatment. J Endourol 2010, 24:799-804. 10.1089/end.2009.0462, 20367408.
27. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 1965, 42:288.
28. Le Bihan D, Breton E. Imagerie de diffusion in-vivo par resonance magnetique nucleaire. C R Acad Sci 1985, 301:1109-1112.
29. Kiricuta IC, Simplaceanu V. Tissue water content and nuclear magnetic resonance in normal and tumor tissues. Cancer Res 1975, 35:1164-1167.
30. Paran Y, et al. Water diffusion in the different microenvironments of breast cancer. NMR Biomed 2004, 17:170-180. 10.1002/nbm.882, 15229930.
31. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol 2007, 188:1622-1635.